BioSpace News Archive

Drug Development

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE.

May 16, 2023
·
5 min read
Business

Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.

May 16, 2023
·
12 min read
Business

Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company’s U.S. commercialization strategy from a clinical and regulatory perspective.

May 16, 2023
·
2 min read
Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

May 16, 2023
·
2 min read
AlzeCure Participates at Penser Market on May 25

AlzeCure Pharma AB announced that the company is participating at Penser Market on May 25 at 14:05 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.

May 16, 2023
·
2 min read
Deals

MindBio Therapeutics Chief Executive Officer Issues Letter to Shareholders Discussing the Company’s Growth Plans

MindBio Therapeutics Corp. today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio.

May 16, 2023
·
8 min read
Pharm Country

Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials

Drug Farm, a private biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has raised the first round of C series financing totaling $27 million USD.

May 16, 2023
·
3 min read
Evaxion to host R&D Day on May 25, 2023

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, announced that it will hold an R&D Day at 12:30 p.m CEST on May 25, 2023.

May 16, 2023
·
1 min read
Drug Development

Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

Locanabio, Inc. announced the presentation of data from its lead vectorized snRNA exon skipping program, LBIO-115, in development for the treatment of Duchenne muscular dystrophy.

May 16, 2023
·
7 min read
Drug Development

Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas

Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas.

May 16, 2023
·
4 min read